Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Weekly paclitaxel vs three‐weekly paclitaxel

Neutropenia · women with recurrent epithelial ovarian cancer

Weekly paclitaxel may leads to lower neutropenia compared with three‐weekly paclitaxel (low certainty).

1 finding from 1 review

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 0.51 [0.27, 0.95]
2 studies · 260 participants
Low

Weekly paclitaxel plus carboplatin vs tri‐weekly paclitaxel plus carboplatin

Grade 3 to 4 neutropenia · first‐line treatment of ovarian cancer

Weekly paclitaxel plus carboplatin showed no clear difference in haematological adverse event: Grade 3/4 neutropenia compared with tri‐weekly paclitaxel plus carboplatin (moderate certainty).

1 finding from 1 review

Weekly versus tri‐weekly paclitaxel with carboplatin for first‐line treatment in women with epithelial ovarian cancer 2022 · Cochrane Headline outcomes only
RR 1.11 [0.86, 1.43]
4 studies · 3639 participants
Moderate